Results 251 to 260 of about 201,990 (292)

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan   +2 more
wiley   +1 more source

Is it Possible To Identify Patients After Their First Hospitalization for a Psychotic Disorder Who Do Not Use Anti-Psychotics and are Not Later Rehospitalized? [PDF]

open access: yesSchizophr Bull
Krivoy A   +12 more
europepmc   +1 more source

Novel Histopathologic Features of Diffuse Blue‐Gray Hyperpigmentation Associated With Kratom Use: A Case Report and Literature Review

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Drug‐induced hyperpigmentation accounts for 10%–20% of acquired pigmentary disorders and can be misdiagnosed for other causes such as melasma, post inflammatory changes, or heavy metal deposition. Kratom (Mitragyna speciosa), a Southeast Asian plant with an opioid‐like profile, has been increasingly used in the United States for ...
Rita Kamoua   +4 more
wiley   +1 more source

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou   +9 more
wiley   +1 more source

Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Objective This observational study examined changes in mental health and wellbeing after 4‐months liraglutide 3.0 mg treatment in patients with obesity and explored associations with weight loss. Methods We included 98 patients with obesity treated with liraglutide 3.0 mg.
Susanne Kuckuck   +7 more
wiley   +1 more source

SNP-based analysis of neuroactive ligand–receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: Data from the CATIE study

open access: green, 2011
Daniel E. Adkins   +6 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy